| __timestamp | AbbVie Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7724000000 | 302156000 |
| Thursday, January 1, 2015 | 6387000000 | 402271000 |
| Friday, January 1, 2016 | 5855000000 | 476593000 |
| Sunday, January 1, 2017 | 6275000000 | 554336000 |
| Monday, January 1, 2018 | 7399000000 | 604353000 |
| Tuesday, January 1, 2019 | 6942000000 | 680924000 |
| Wednesday, January 1, 2020 | 11299000000 | 737669000 |
| Friday, January 1, 2021 | 12349000000 | 759375000 |
| Saturday, January 1, 2022 | 15260000000 | 854009000 |
| Sunday, January 1, 2023 | 12872000000 | 937300000 |
| Monday, January 1, 2024 | 14752000000 | 1009025000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Over the past decade, AbbVie Inc. and BioMarin Pharmaceutical Inc. have demonstrated contrasting approaches to their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie Inc. has seen a significant increase in SG&A expenses, peaking in 2022 with a 97% rise from 2014 levels. This reflects their aggressive expansion and marketing strategies. In contrast, BioMarin's SG&A expenses have grown more modestly, with a 210% increase over the same period, indicating a more conservative approach. The data highlights how these companies prioritize their resources, with AbbVie focusing on rapid growth and BioMarin maintaining steady progress. As the pharmaceutical landscape continues to shift, these spending patterns offer insights into each company's strategic priorities and market positioning.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Summit Therapeutics Inc.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
AbbVie Inc. or TG Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Amgen Inc. and BioMarin Pharmaceutical Inc.
Who Optimizes SG&A Costs Better? BioMarin Pharmaceutical Inc. or Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Verona Pharma plc
BioMarin Pharmaceutical Inc. and Jazz Pharmaceuticals plc: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of BioMarin Pharmaceutical Inc. and Alkermes plc
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for BioMarin Pharmaceutical Inc. and Mesoblast Limited
BioMarin Pharmaceutical Inc. vs Geron Corporation: SG&A Expense Trends